Dr. Ann Killoran, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 342
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
IA license 43665
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
Medical groups
- State University of Iowa (1,897 clinicians)
- Progressive Rehabilitation Associates LLC (287 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 342
- Services billed
- 629
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 194 | 163 |
| Established patient office or other outpatient visit, 40-54 minutes | 86 | 68 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 63 | 24 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 59 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 57 | 52 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 51 | 23 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 26 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Iowa City, IA | 828 |
| Amantadine (amantadine hcl) Other prescribers in Iowa City, IA | 218 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Iowa City, IA | 214 |
| Ropinirole Hcl Other prescribers in Iowa City, IA | 211 |
| Donepezil Hcl Other prescribers in Iowa City, IA | 200 |
| Quetiapine Fumarate Other prescribers in Iowa City, IA | 136 |
| Gabapentin Other prescribers in Iowa City, IA | 135 |
| Tetrabenazine | 117 |
| Rivastigmine (rivastigmine tartrate) Other prescribers in Iowa City, IA | 117 |
| Austedo (deutetrabenazine) Other prescribers in Iowa City, IA | 100 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $154,647 in research payments for these studies, mostly to the institutions running them.
- Phase II dose finding study in prodromal early manifest HD individuals
Genentech, Inc. - An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
UCB SA · Terminated · NCT05543252 - A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
Sage Therapeutics, LLC - Epidemiology Study
Roche Tcrc, Inc. - Epidemiology Study
Genentech, Inc. - A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Sage Therapeutics, LLC - A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
UCB SA · Completed · NCT04658186
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.